SCM heads into the week after earnings with a familiar tension: insiders who loaded up at distressed prices in March now watching that recovery stall.
The insider angle is the most compelling feature of this setup. In a concentrated cluster on March 13, CEO Robert Ladd bought 35,000 shares at $8.70, CFO Todd Huskinson added 5,700 at $8.79, and independent director Bruce Bilger accumulated roughly 45,000 shares across multiple tranches near the same level. Ladd followed up with a further 1,700-share purchase on March 16. Combined, the 90-day net insider buying totals nearly 88,000 shares worth approximately $766,000. That is not a token gesture — the CEO and CFO both put meaningful personal capital to work at the lows.
The borrow market has shifted sharply since that March cluster. Cost to borrow peaked near 8% in mid-April and has since collapsed to 2.5% — a drop of roughly 55% in a single week. Availability is ample at around 405% of short interest, meaning the pool of shares available to lend dwarfs the current short position by a wide margin. Short interest itself is negligible relative to the float, with the ORTEX short score easing from 51.3 on April 29 to 43.4 by May 12. That declining score, combined with loosening borrow conditions, points to shorts reducing rather than building. What looked like a contested name six weeks ago has become a quieter one in the lending market.
The Street's recent posture is cautious rather than hostile. Ladenburg Thalmann's Christopher Nolan cut his price target to $11 from $12 yesterday — the most recent analyst action — while keeping a Buy rating. That leaves a meaningful gap between the current $9.39 price and even the most recently lowered buy-side target. The only other recent action of note was Keefe, Bruyette & Woods trimming to $9 in March, which briefly aligned with where the stock was actually trading. With the mean analyst target at $13.10, there is a wide dispersion of views that likely reflects uncertainty around net investment income and portfolio credit quality rather than conviction in either direction. The snapshot's analyst consensus data carries a staleness caveat — the aggregate $13.10 target dates to November 2025 — so treat that figure as background context rather than current Street consensus.
The stock fell 3.7% on May 11 following its earnings release, pulling back from the recovery that followed the March insider buying. At $9.39, SCM trades at a price-to-book of roughly 0.77 — below NAV, which has historically been the level that attracts value buyers into BDCs. The earnings yield implied by current pricing sits near 11%. For a business development company, those metrics carry meaning only if the dividend and NAV hold; the post-earnings price reaction suggests the market found something in the latest print to question. The next earnings event is pencilled in for June 16 — that print will be the cleaner read on whether the March insider conviction was well-timed or premature.
Peers were mixed on the week. ARCC fell about 3% and HTGC dropped 3.6%, suggesting sector-wide pressure rather than an SCM-specific story. CGBD and OWL fared worse, both off nearly 7% over the same period, while GLAD managed a slight gain. The relative outperformance of some peers and the shared weakness across others makes the post-earnings SCM reaction look more like macro BDC pressure than a company-specific blow-up — though the June print will test that read.
The question heading into June 16 is whether the March insider cluster reflects genuine management confidence in near-term NAV stability, or whether it was an early call that needs a few more quarters to play out.
See the live data behind this article on ORTEX.
Open SCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
